Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.
A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.
Zika developments continued at an accelerated pace this week with the WHO saying that India's Bharat Biotech and the U.S. National Institutes of Health are farthest along in vaccine development.
While H7N9 avian flu does not seem to move easily from person to person, the WHO notes that most people who catch it become severely ill. Several candidates for H7N9 pandemic flu have proven safe and immunogenic in clinical trials, but experts recommend that these be beefed up for practical use either via multiple doses or using an adjuvant. The National Institute of Allergy and Infectious Diseases reported Thursday that a team of scientists has successfully tested a prime-boost vaccine for the flu strain in a small clinical trial.
No specific treatment or vaccine currently exists for the mosquito-borne Chikungunya virus, but efforts are underway to remedy that. The NIH's National Institute of Allergy and Infectious Diseases (NIAID) will bring its experimental vaccine into Phase II, keeping up with Austria's Themis, which raised $7.9 million to do the same for its candidate last May.
A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.
The mosquito-borne West Nile virus has infected more than 41,000 people and killed more than 1,700 people in the U.S. since 1999. But while there is an effective veterinary vaccine for the virus, there is no commercially available human vaccine. The National Institutes of Health's NIAID is launching a Phase I trial of a human vaccine at Duke University.
NIH advice on early HIV treatment could boost sales at Gilead, GSK, J&J; and BMS
U.S. federal health officials said patients should take antiretroviral meds as soon as they are diagnosed instead of waiting to start therapy, potentially opening the door for increased sales of the drugs.
The race for an Ebola vaccine is ramping up with positive Phase I data from an experimental vaccine made by GlaxoSmithKline and the NIH's National Institute of Allergy and Infectious Diseases. And thanks to those results, larger trials could be on the way soon.
PATH chooses Mymetics for work on transmission-blocking malaria vaccine
With a brand-new $156 million Gates Foundation grant in hand, the PATH Malaria Vaccine Initiative has signed on Switzerland-based Mymetics to develop and produce virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate.